Literature DB >> 35030148

Trans-scleral incision for peeling subretinal proliferation tissue in Grade C proliferative vitreoretinopathy.

Wen Fan1, Han Shen, Na Su, Songtao Yuan.   

Abstract

PURPOSE: The purpose of this study was to investigate the clinical outcomes of optimized method in order to clearly remove the subretinal proliferative tissue by trans-scleral puncture into the subretinal space in Grade C proliferative vitreoretinopathy (PVR) patients without inducing retinal injury.
METHODS: This was a prospective clinical observation study. Eight consecutive patients who had undergone optimized vitrectomy surgery for retinal detachment complicated by Grade C proliferative vitreoretinopathy were investigated. Subretinal proliferation was cleared by adding one additional scleral 23-gauge trocar under the detached retina at 9-10 mm from limbus. After the sclera is pierced, the puncture knife changed its direction without touching the retina. 23G intraocular forceps were used to remove the proliferation strand or membrane through the puncture channel.
RESULTS: Retinal reattachment was achieved in each case without a retinotomy. The mean best-corrected visual acuity (BCVA) was improved within the first 1 month (P = 0.039) and remained stable at the following phase. There were no postoperative complications, such as reoccurrence of retinal detachment or proliferative vitreoretinopathy. No postoperative hemorrhage or hypotension was observed.
CONCLUSION: The satisfying results demonstrated the feasibility of this cost-effective, easy-to-follow, trans-scleral vitrectomy method in treating retinal detachment with Grade C PVR.
Copyright © 2022 by Ophthalmic Communications Society, Inc.

Entities:  

Year:  2022        PMID: 35030148     DOI: 10.1097/IAE.0000000000003391

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Evaluation of Ab externo subretinal bands removal during pars plana vitrectomy for rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy.

Authors:  Samir Elbaha; Mohammed Ghoneem; Amir Abousamra; Mahmoud Abouhussein
Journal:  BMC Ophthalmol       Date:  2022-05-20       Impact factor: 2.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.